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Abstract:  
Hepatocellular carcinoma (HCC) is an aggressive cancer associated with high mortality 
worldwide. HCC develops in the setting of underlying cirrhosis due to chronic liver disease. 
Surgery is usually considered the treatment of choice for early disease however most patients 
have locally advanced or metastatic HCC at diagnosis in which case treatments are limited. 
Immune checkpoint blockade of programmed death receptor-1 (PD-1) pathway offers a potential 
treatment strategy based on the encouraging results of the phase I/II trial of nivolumab 
(Checkmate 040 trial).  This has led to the off-label use of nivolumab after failure of treatment 
with sorafenib either due to intolerance or progression of disease.  Although rare (<5%), clinical 
response to anti-PD-1 antibody may be preceded by “pseudoprogression” –  increase in the size 
and number of tumor lesions before actual tumor shrinkage. We report a case of 
pseudoprogression followed by excellent response in a HCC patient treated with nivolumab and 
review the literature for ongoing trials of immune checkpoint blockade in HCC.  The 
pseudoprogression in our case is supported by both increase in tumor size as well as alpha-
fetoprotein after four treatments with nivolumab however regression of tumor size and 
normalization of alpha-fetoprotein after subsequent treatments. To our knowledge, there are no 
reports of pseudoprogression in HCC although pseudoprogression has been well described in 
melanoma. 
 
 
 
 
 
 
 
 
Introduction: 
Hepatocellular carcinoma (HCC) is the primary malignancy of the liver that often occurs 
in the setting of underlying chronic liver disease and cirrhosis. It is the second leading cause of 
cancer related death worldwide (Jemal et al., 2011). In the United States, annual incidence of 
HCC is 6 per 100,000 (El-Serag & Kanwal, 2014). Although the US is considered a low 
incidence area for HCC, the incidence has increased over the past two decades, likely due to a 
large cohort of people with chronic hepatitis C (Davila et al., 2004). Other risk factors for HCC 
include chronic hepatitis B or C infection, and alcoholic liver disease. Nonalcoholic fatty liver 
disease (NAFLD)/ nonalcoholic steatohepatitis (NASH) is an emerging risk factor that is 
increasingly becoming more prevalent. Other less common risk factors are hereditary 
hemochromatosis, alpha 1- antitrypsin deficiency, autoimmune hepatitis, and Wilson’s disease 
(El-Serag, 2011).  
The treatment choice for HCC is predominantly driven by the extent of tumor and the 
degree of underlying liver dysfunction. Surgical resection or orthotopic liver transplant (OLT) 
offer the best chance of cure, however these treatments are applicable to a small minority of 
patients (Waller et al., 2015). Liver directed therapies in the form of transarterial 
chemoembolization (TACE), or radiofrequency ablation (RFA) are frequently utilized for more 
advanced disease (Chok et al., 2014). However, approximately 50% of patients are diagnosed 
with locally advanced or metastatic disease, and therefore, are not eligible for potentially 
curative treatments (SEER, 2017).  Also, patients treated with locoregional therapy generally 
progress to disease that is too advanced for that modality.  Being a relatively chemotherapy 
refractory tumor, the treatment options for advanced HCC are extremely limited. The only 
systemic treatment currently approved for the treatment of advanced disease is sorafenib, 
yielding a median overall survival of 6.5-10.7 months in patients with good liver function (Llovet 
et al., 2008). Therefore, a search for novel therapeutic agents is necessary (Cheng et al., 2009;  
Llovet et al., 2008). 
In recent years, immunotherapy in the form of immune checkpoint blockade has brought 
a paradigm shift in cancer treatment. Being an ‘immune privileged’ organ, the liver presents a 
unique opportunity to exploit modification of immune regulatory pathways as a potential 
therapeutic strategy for HCC (Flecken et al., 2012). The liver confronts abundant exogenous 
antigens within blood from the gut via the portal vein. Specific mechanisms with regards to 
immune tolerance are activated to inhibit unneeded immune responses. Unfortunately, these 
mechanisms, such as recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor 
cells, and overexpression of inhibitory ligands such as programmed death ligand 1 (PD-L1), 
contribute to weakened anti-tumor immune responses and ultimately tumor progression (Hong 
et al., 2015).  
Blockade of immune checkpoint pathways such as the programmed death receptor – 1 
(PD-1) pathway or the cytotoxic T lymphocyte antigen – 4 (CTLA-4) pathway can potentially 
offer a treatment strategy to reinstate host immune response against HCC and ultimately tumor 
regression. Encouraging results of a phase I/II trial of nivolumab (Checkmate 040 trial) (El-
Khoueiry, 2016) has led many oncologists to use nivolumab for treating HCC patients especially 
in the second line setting (after sorafenib).  Assessment of clinical efficacy for immune 
checkpoint inhibitors presents a unique challenge due to possibility of “pseudoprogression” – 
increase in the size and number of tumor lesions before tumor shrinkage (Chiou & Burotto, 
2015;  Hodi et al., 2016). We report a case of HCC that had an excellent response to treatment 
with nivolumab after initial pseudoprogression.   
 
 
Case Presentation: 
A 79-year-old man with diabetes mellitus, hypertension, hyperlipidemia, and 
hypothyroidism presented with worsening back pain and found to have large heterogeneous 
irregular mass within the right hepatic lobe on CT imaging. A subsequent MRI abdomen showed 
at least 2 hepatic lesions with the largest measuring up to 7.9 x 7.6 cm in dimension with 
nonspecific imaging characteristics. Serum alpha-fetoprotein (AFP) was 117 ng/mL at that time. 
Because of the lack of characteristic radiologic appearance of the liver lesions for HCC 
(hyperenhancement during arterial phase and delayed washout in venous phase), he underwent 
ultrasound guided core needle biopsy of the lesion in segment 8 which confirmed the diagnosis 
of well differentiated hepatocellular carcinoma in a background of cirrhosis secondary to 
hemochromatosis and NASH (Figure 1A). Viral infection was ruled out.  He was initially treated 
with sorafenib and ipafricept on a clinical trial due to multifocal disease and good liver function 
(Child-Pugh class A cirrhosis).  Ipafricept is a fusion protein comprised of the cysteine-rich 
domain of frizzled family receptor 8 (Fzd8) fused to the human immunoglobulin Fc domain with 
potential antineoplastic activity.  Despite doing clinically well, he had radiographic progression of 
disease after 4 months of treatment.   
Due to lack of an available clinical trial, he was started on off-label nivolumab (3  
mg/kg IV every 2 weeks) based on the phase II data mentioned above (El-Khoueiry et al., 
2015).  Baseline computed tomography (CT) showed two large liver lesions but no extrahepatic 
disease (Figure 1 A).  Restaging CT after 4 cycles of nivolumab showed increase in the size of 
the liver lesions but no new lesions (Figure 1 B).  At this time, his alpha-fetoprotein (AFP) also 
increased to 3,246 ng/mL as compared to 1,232 ng/mL before nivolumab was started.  The 
patient was continued on nivolumab due to lack of any other effective treatments, clinical 
stability, and possibility of pseudoprogression.  Repeat imaging after 8 cycles of nivolumab (4 
months) showed significant decrease in the size of the liver lesions and AFP decline to 68 
ng/mL.  The patient remained on biweekly treatments with bimonthly restaging scans.  His 
tumor size continued to decrease until cycle 12 of nivolumab, and remained stable thereafter 
until last restaging after cycle 19 (9 months) of nivolumab.  Similarly, his AFP continued to 
decrease until cycle 12 of nivolumab, and become normal (< 25 ng/ml) thereafter until last 
restaging after cycle 19 (9 months) of nivolumab.  
  
Discussion: 
We report a case of HCC in the setting of cirrhosis from hemochromatosis and NASH 
that had an excellent response to off-label use nivolumab and take this opportunity to review the 
literature for anti-PD1 therapy in HCC and highlight a key observation in this regard – 
pseudoprogression.  Although HCC is the second most frequent cause of cancer mortality 
worldwide, sorafenib remains the only chemotherapy option for the treatment of advanced HCC.  
Notably, sorafenib has shown an improvement in median OS in phase III placebo-controlled trial 
from 7.9 months to 10.7 months however the objective response rate is low (2.2%) and 
treatment is often complicated by underlying liver dysfunction requiring dose reduction to avoid 
treatment related toxicity (Llovet et al., 2008).  
In recent years, immune checkpoint blockade has brought a paradigm shift in the 
treatment of a number of malignancies.  Various immune checkpoint blocking agents are being 
tested for their efficacy in HCC.  There are several ongoing trials with immune checkpoint 
blockade in HCC (Table 1).  The PD-1/PD-L1 pathway downregulates the immune response by 
suppressing antigen-specific T cell activation.  PD-1 receptors are expressed on several 
immune cells including B cells, myeloid cell, T cells and NK cells. The PD-L2 is only expressed 
on dendritic cells whereas PD-L1 is expressed on dendritic cells, blood vessels, myocardium, 
lung, and placenta. Similarly, the CTLA-4 pathway also downregulates T-cell immune responses 
by regulating the proliferation of T lymphocytes however CTLA-4 is mainly expressed on Tregs 
and the CTLA-4 pathway functions solely within the lymph nodes (Kudo, 2017).  
We conducted a thorough English literature search on PubMed using the search terms 
‘anti-PD1’, ‘pembrolizumab’ or ‘nivolumab’ and ‘hepatocellular cancer’, ‘HCC’ or ‘hepatoma’. 
There are no published data from randomized controlled trial of checkpoint inhibitors in HCC, 
however, results of a phase I/II trial of nivolumab (CheckMate 040) in patients with HCC have 
generated significant excitement (El-Khoueiry et al., 2015;  Sangro, 2016). Besides the 
CheckMate 040 trial, we only found a case report of a metastatic HCC patient successfully 
treated with pembrolizumab after progression on sorafenib (Truong et al., 2016). Notably, there 
are many ongoing trials evaluating the safety and efficacy of checkpoint inhibitors in HCC 
(Table 1). 
Nivolumab is a fully humanized IgG4 monoclonal antibody to programmed cell death 
receptor-1 (PD-1) that has shown apparent efficacy in HCC  (Sangro, 2016). In the CheckMate 
040 trial, a total of 214 advanced HCC patients with Child-Pugh score ≤ 6 were treated into 3 
separate expansion cohorts: HCV-infected, HBV-infected and uninfected (sorafenib 
naïve/intolerant and sorafenib progressors). Objective responses were seen in 35 of 214 (16%) 
including 2 complete responses (CR) and 33 partial responses (PR) regardless of the etiologic 
subtype, PD-L1 status or cohort (El-Khoueiry et al., 2015;  Sangro, 2016). Responses were 
durable, lasting for 14–17+ months for CR and up to 8 months for PR. Time to tumor response 
was 3 months, however the median duration of response has not yet been reached. The overall 
survival rate for all patients combined together was 82.5% and 70.8% at 6 and 9 months, 
respectively.  
Treatment related grade 3 or 4 adverse events were seen in 18% patients; most 
commonly an asymptomatic elevation in AST and ALT (Sangro, 2016). Based on the 
encouraging results of Checkmate 040, a multinational phase III randomized controlled trial, 
(CheckMate 459) (NCT02576509) (NCT02576509) is currently ongoing with a primary endpoint 
of overall survival and time to tumor progression. The trial will randomize (1:1) systemic therapy 
naive HCC patients to either sorafenib or nivolumab (3 mg/kg Q 2 weekly) with a planned 
enrollment of 726 patients.  
It is not surprising to see clinical benefit with immune checkpoint blockade in infected 
HCC (those with hepatitis B or C infection), since both these infections are associated hepatic 
inflammation and upregulation of PD-1 (Barathan et al., 2015;  Xu et al., 2014). Interestingly, in 
CheckMate 040, about a third of the patients were uninfected and both CRs were seen in 
uninfected patients. In addition, both these patients had longer than median duration of 
response.  
Our case highlights some important aspects of use of nivolumab in HCC. Firstly, we 
observed pseudoprogression followed by excellent and durable response to anti-PD1 therapy. 
Pseudoprogression has not been described in HCC. Although the overall incidence of 
pseudoprogression is low (< 5%) even in melanoma (Hodi et al., 2016), oncologists treating 
HCC patients with immune checkpoint blockade therapy should be aware of the possibility of 
pseudoprogression, which may manifest as increase in AFP as well as tumor size.  While the 
mechanism of pseudoprogression is not fully elucidated, transient increase in tumor size is 
believed to be secondary to immune cell infiltration and necrosis (Chiou & Burotto, 2015).  The 
case may assist in clinical decision making especially for oncologists not familiar with Immune-
Related Response Criteria. Secondly, unlike chronic hepatitis, uninfected HCC (such as, 
induced by hemochromatosis and NASH) is not known to be associated with upregulation of 
PD-1 or PDL-1, yet treatment with nivolumab in this setting seems to be beneficial. Notably, our 
patient’s tumor lacked expression of PD-L1 (Figure 1B) but still had good response raising 
question about the value of PD-L1 testing as a biomarker in HCC.  
In summary, we present a case of uninfected HCC treated successfully with anti-PD1 
antibody (nivolumab) after pseudoprogression. The results from Checkmate 049 will add to our 
knowledge of anti-PD1 therapy in the treatment of HCC and provide more information about the 
phenomenon of pseudoprogression.   
 
 
 
 
 
  
 
Table 1: Ongoing clinical trials with immune checkpoint blockade in HCC. 
Agent N Trial 
Phase 
Line of 
Therapy 
Primary 
Endpoint 
Status 
Anti PD-1 Ab 
Nivolumab 
(NCT01658878) 
CheckMate 040 
576 + 
Cohort 5 
I/II 
 
First and 
Second  
 
DLT, MTD 
and ORR 
Recruiting 
Nivolumab 
(NCT02576509) 
CheckMate459 
726 III First  
 
OS and TTP 
 
Recruiting 
Nivolumab and CC-
122 (NCT02859324) 
50 I/II 
 
First DLT, AE and 
ORR 
Recruiting 
Pembrolizumab  
(NCT02702414)  
KEYNOTE-224  
100 II Second  ORR Completed 
Pembrolizumab 
(NCT02940496) 
15 I/II 
 
Second Predictive 
Biomarkers 
Recruiting 
Pembrolizumab 
(NCT02658019) 
28 II Second  DCR and AE Recruiting 
Pembrolizumab 
(NCT02702401)  
KEYNOTE-224 
408 III Second  PFS and OS Recruiting 
Pembrolizumab 
(NCT03062358) 
KEYNOTE-394 
330 
Asian 
Subjects 
III Second OS Recruiting 
Pembrolizumab and 
Lenvatinib  
(NCT03006926) 
30 Ib First DLT and AE Recruiting 
Anti PD-L1 Ab 
Durvalumab 
(MEDI4736) and 
Tremelimumab  
(NCT02519348) 
144 II First and 
Second  
Safety and 
Tolerability 
Recruiting 
Durvalumab 
(MEDI4736) and 
Tremelimumab  
(NCT02572687) 
114 I Second DLT Recruiting 
Anti CTLA-4 Ab 
CP-675,206 
(NCT01008358) 
20 II Second Tumor 
response 
Completed 
 
Abbreviations: ORR, Objective Response Rate; OS, Overall Survival; PFS, Progression Free 
Survival; DLT, Dose Limiting Toxicity; AE, Adverse Effect; DCR, Disease Control Rate; BSC, 
Best Supportive Care. 
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